Over 1.3 billion US dollars! Biogen and Capsigen collaborate to develop gene therapy

Biogen and Capsigen recently announced that the two companies have signed a strategic research cooperation agreement to design a new type of adeno-associated virus capsids (AAVcapsids) with the potential to deliver transformative gene therapies to address a variety of central nervous systems and nerves.
Potential genetic causes of muscle diseases
.
This collaboration is intended to treat central nervous system and neuromuscular diseases

According to the terms of the agreement, Capsigen will apply its vector engineering methods to develop highly customized new capsids that meet the characteristics of disease-specific transduction
.
Bojian will obtain the exclusive license of Capsigen's proprietary technology to develop gene therapies that target multiple (undisclosed numbers) of central nervous system and neuromuscular diseases

It is understood that this collaboration will use Capsigen's proprietary TRADE platform and related technologies to create and identify customized new adeno-associated virus capsids that meet disease-specific transduction characteristics
.
The capsid is the protein coat of the virus, which can protect and promote the gene load of the virus into the host cell